In this groundbreaking episode, we will dive into OpenAI’s latest leap from chatbots to biological AI with their new model, GPT-4 B Micro, designed to revolutionize longevity research. Discover how this innovation could turbocharge stem cell production, combat aging, and reshape regenerative medicine—all while unpacking Sam Altman’s $555 million bet on life extension startups. Key Topics Covered: OpenAI’s Biological AI Model: How GPT-4 B Micro improves Yamanaka factors to reprogram cells 50x more efficiently—a potential game-changer for anti-aging. Sam Altman’s Longevity Obsession: His $180M investment in Retro Biosciences, a startup aiming to add 10+ years to human lifespan through cellular reprogramming and AI. The Science of Immortality: Breaking down stem cell magic, age-related diseases, and why Silicon Valley giants like Google and Jeff Bezos are pouring billions into longevity. Ethical Dilemmas: Altman’s cautionary stance on balancing AI’s power to “cure diseases or create new ones.” Industry Trends: From Calico Life Sciences to Altos Labs, why tech moguls are betting big on turning aging from “inevitable” to “treatable.” Join Julia for an in-depth discussion on one of the most critical challenges facing the future of AI development and economic prosperity. Connect with Julia: YouTube: https://youtube.com/juliamccoy Instagram: https://www.instagram.com/juliaemccoy/ X: https://x.com/juliaemccoy